Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Cancer, Animal models, Diagnostics & prognostics

Rush at Your Peril

I have now been working in the field of cancer biomarker discovery for over 30 years. The investment over the last decade or so has been high – as has the excitement – but, in my opinion, the actual yield of new cancer biomarkers has been very poor. 

There are many reasons for this, but I believe there is a major problem that needs to be tackled: false discovery. All too often, a group will believe that they have discovered a new biomarker, and they will hurry to publish in a prestigious journal. And all too often, it becomes apparent that the biomarker is not performing as expected, and that the results are unreliable and can’t be reproduced. In short, the discovery is a false one.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Eleftherios P. Diamandis

Eleftherios P. Diamandis is Hold'em for Life Chair in Prostate Cancer Biomarkers, Head of Clinical Biochemistry, Mount Sinai Hospital and University Health Network; Professor & Head, Division of Clinical Biochemistry, Department of Laboratory Medicine & Pathobiology, University of Toronto.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register